Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer

A phase III randomized trial was conducted in patients with metastatic NSCLC, to determine if, in association with mitomycin (6 mg m–2) and ifosfamide (3 g m–2), the combination of moderate dosages of cisplatin (60 mg m–2) and carboplatin (200 mg m–2) – CarboMIP regimen – improved survival in comparison with cisplatin (50 mg m–2) alone – MIP regimen. A total of 305 patients with no prior chemotherapy were randomized, including 297 patients assessable for survival (147 in the MIP arm and 150 in the CarboMIP arm) and 268 patients assessable for response to chemotherapy. All but eight (with malignant pleural effusion) had stage IV disease. There was a 27% (95% CI, 19–34) objective response (OR) rate to MIP (25% of the eligible patients) and a 33% (95% CI, 24–41) OR rate to CarboMIP (29% of the eligible patients). This difference was not statistically significant (P = 0.34). Duration of response was not significantly different between both arms. There was also no difference (P = 0.67) in survival: median survival times were 28 weeks (95% Cl, 24–32) for MIP and 32 weeks (95% Cl, 26–35) for CarboMIP, with respectively 1-year survival rates of 24% and 23% and 2-year survival rates of 5% and 2%. The main toxicities consisted in emesis, alopecia, leucopenia and thrombocytopenia, that were, except alopecia, significantly more severe in the CarboMIP arm. Our trial failed to demonstrate a significant improvement in response or survival when patients with metastatic NSCLC were treated, in addition to ifosfamide and mitomycin, by combination of moderate dosages of cisplatin and carboplatin instead of moderate dosage of cisplatin alone. The results support the use of a moderate dose (50 mg m–2) of cisplatin in combination with ifosfamide and mitomycin for the chemotherapy of this disease. © 2000 Cancer Research Campaig

Concomitant chemoradiotherapy in locally advanced non-samll cell lung cancer (NSCLC) using weekly Taxol, daily Carboplatin and hyperfractionated radiotherapy

0info:eu-repo/semantics/publishe

Comparison of two chemotherapy regimens, in stage IV non small cell lung cancer (NSCLC), based on cisplatin or on the combination of cisplatin and carboplatin: a randomized trial conducted by the European Lung Cancer Working Party

36th ASCO Meeting, NEW Orleans, 20-23/05/2000info:eu-repo/semantics/publishe

Etude randomisée comparant deux combinaison de chimiothérapie dans les cancers bronchiques non à petites cellules (CBPNC) au stade IV, l'une avec du cisplatine seul (50 mg/m²) et l'autre avec une association de doses modérées de cisplatine et de carboplatine.

4e Congrès de Pneumologie de Langue Française, Nice, Acropolis, 26-29/01/2000info:eu-repo/semantics/publishedsuppl1: 1S68 (135)

A randomised trial comparing chemotherapy regimens with cisplatin (50mg/m2) versus moderate doses of cisplatin and carboplatin in stage IV non-small cell lung cancer

ERS Annual Congress, Madrid, Espagneinfo:eu-repo/semantics/publishedsuppl 30,7s (142

Evaluation of the TN sub-staging in patients with initially unresectable stage III non-small cell lung cancer treated by induction chemotherapy

PurPose: This study attempted to investigate, in a cohort of patients with clinical stage III initially unresectable non-small cell lung cancer (NSCLC) treated by the same induction chemotherapy regimen, the prognostic value of clinical T and N sub-groupings in order to validate the current International Staging System (ISS). Patients and methods: All the eligible patients with stage III NSCLC (428 patients) registered in a clinical trial were included in the study investigating, after three courses of induction chemotherapy, the role, in responders, of chest irradiation in comparison to further chemotherapy. The chemotherapy regimen consisted of mitomycin C, ifosfamide and cisplatin. Results: Patients with ISS 1986 stage IIIA had a significantly better survival than those with stage IIIB (median survival 47 vs 36 weeks; P=0.01). A RECPAM analysis showed that patients with T1-T2 N3 and T4 N0-1-2 stage had a more similar prognosis to those with stage IIIA. That result leads to define two new sub-groups: stage IIIα (T3-T4 N0-N1; any T N2; T1-T2 N3) and IIIβ (T3-T4 N3), with a highly significant difference in survival between them (median survival: 45 vs 29 weeks; P<0.0001).The superiority of that new classification on the ISS documented in our series of stage III patients for discriminating survival and tumour response has to be confirmed on another series in a multivariate context. Conclusion: For unresectable NSCLC treated by induction chemotherapy, stage III sub-classification by moving T4 N0-1 and T1-2 N3 tumours from stage IIIB to stage IIIA appeared to better correlate with prognosis. The usefulness of this new sub-division has to be tested in validation studies. Copyright (C) 1998 Elsevier Science Ireland Ltd.SCOPUS: ar.jinfo:eu-repo/semantics/publishe

Prognostic factors analysis for response to chemotherapy and survival in a prospective cohort of patients with unresectable locoregional non small cell lung cancer initially treated by induction chemotherapy

info:eu-repo/semantics/publishe

A three-arm phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small-cell lung cancer

SCOPUS: ar.jinfo:eu-repo/semantics/publishe

A randomised phase III trial comparing consolidation treatment with further chemotherapy to chest irradiation in patients with initially unresectable locoregional non-small-cell lung cancer responding to induction chemotherapy

SCOPUS: ar.jinfo:eu-repo/semantics/publishe